Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:623-629
Published online before print January 31, 2002, doi: 10.1161/01.ATV.0000012283.15789.67
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
22/4/623    most recent
01.ATV.0000012283.15789.67v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vincent, L.
Right arrow Articles by Hong, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vincent, L.
Right arrow Articles by Hong, L.
Related Collections
Right arrow Angiogenesis
Right arrow Cell biology/structural biology
Right arrow Cell signalling/signal transduction
Right arrow Mechanism of atherosclerosis/growth factors
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:623.)
© 2002 American Heart Association, Inc.


Vascular Biology

Cerivastatin, an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, Inhibits Endothelial Cell Proliferation Induced by Angiogenic Factors In Vitro and Angiogenesis in In Vivo Models

Loïc Vincent; Claudine Soria; Farrokh Mirshahi; Paule Opolon; Zohair Mishal; Jean-Pierre Vannier; Jeannette Soria; Li Hong

From Laboratoire DIFEMA (L.V., C.S., F.M., J.-P.V., L.H.), UFR de Médecine et Pharmacie, Rouen, France; INSERM U553 (C.S.), Hôpital Saint Louis, Paris, France; Institut Gustave Roussy (P.O.), Villejuif, France; CNRS (Z.M.), IFR 2249, Villejuif, France; and Laboratoire de Biochimie and EMI 99-12 (J.S.), Hôtel-Dieu, Paris, France.

Reprint requests to Claudine Soria, Laboratoire DIFEMA, UFR de Médecine et Pharmacie, 22 Boulevard Gambetta, 76183 Rouen, France. E-mail claudine.soria{at}lrb.ap-hop-paris.fr

Cerivastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. It inhibits the biosynthesis of cholesterol and its precursors: farnesyl pyrophosphate and geranylgeranyl pyrophosphate (GGPP), which are involved in Ras and RhoA cell signaling, respectively. Statins induce greater protection against vascular risk than that expected by cholesterol reduction. Therefore, cerivastatin could protect plaque against rupture, an important cause of ischemic events. In this study, the effect of cerivastatin was tested on angiogenesis because it participates in plaque progression and plaque destabilization. Cerivastatin inhibits in vitro the microvascular endothelial cell proliferation induced by growth factors, whereas it has no effect on unstimulated cells. This growth arrest occurs at the G1/S phase and is related to the increase of the cyclin-dependent kinase inhibitor p21Waf1/Cip1. These effects are reversed by GGPP, suggesting that the inhibitory effect of cerivastatin is related to RhoA inactivation. This mechanism was confirmed by RhoA delocalization from cell membrane to cytoplasm and actin fiber depolymerization, which are also prevented by GGPP. It was also shown that RhoA-dependent inhibition of cell proliferation is mediated by the inhibition of focal adhesion kinase and Akt activations. Moreover, cerivastatin inhibits in vivo angiogenesis in matrigel and chick chorioallantoic membrane models. These results demonstrate the antiangiogenic activity of statins and suggest that it may contribute to their therapeutic benefits in the progression and acute manifestations of atherosclerosis.


Key Words: statins • angiogenesis inhibition • RhoA • vascular risk




This article has been cited by other articles:


Home page
IOVSHome page
M. Bartoli, M. Al-Shabrawey, M. Labazi, M. A. Behzadian, M. Istanboli, A. B. El-Remessy, R. W. Caldwell, D. M. Marcus, and R. B. Caldwell
HMG-CoA Reductase Inhibitors (Statin) Prevents Retinal Neovascularization in a Model of Oxygen-Induced Retinopathy
Invest. Ophthalmol. Vis. Sci., October 1, 2009; 50(10): 4934 - 4940.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
M. Rodriguez-Yanez, J. Agulla, R. Rodriguez-Gonzalez, T. Sobrino, and J. Castillo
Review: Statins and stroke
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 157 - 166.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
F. D. Kolodgie, J. Narula, C. Yuan, A. V. Finn, H. K. Gold, and R. Virmani
Reply
J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1521 - 1521.
[Full Text] [PDF]


Home page
Hum ReprodHome page
M. Oktem, I. Esinler, D. Eroglu, N. Haberal, N. Bayraktar, and H. B. Zeyneloglu
High-dose atorvastatin causes regression of endometriotic implants: a rat model
Hum. Reprod., May 1, 2007; 22(5): 1474 - 1480.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
X.-Y. Zhu, E. Daghini, A. R. Chade, C. Napoli, E. L. Ritman, A. Lerman, and L. O. Lerman
Simvastatin Prevents Coronary Microvascular Remodeling in Renovascular Hypertensive Pigs
J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1209 - 1217.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, and F. Fyhrquist
Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1917 - H1921.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
H. Xu, L. Zeng, H. Peng, S. Chen, J. Jones, T.-L. Chew, M. M. Sadeghi, Y. S. Kanwar, and F. R. Danesh
HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation
Am J Physiol Renal Physiol, November 1, 2006; 291(5): F995 - F1004.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. Yao, R.-H. Zhou, M. Petreaca, L. Zheng, J. Shyy, and M. Martins-Green
Activation of sterol regulatory element-binding proteins (SREBPs) is critical in IL-8-induced angiogenesis
J. Leukoc. Biol., September 1, 2006; 80(3): 608 - 620.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
H. J. Zambarakji, T. Nakazawa, E. Connolly, A. M. Lane, S. Mallemadugula, M. Kaplan, N. Michaud, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller
Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization.
Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2623 - 2631.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T.-S. Li, M. Takahashi, R. Suzuki, T. Kobayashi, H. Ito, A. Mikamo, and K. Hamano
Pravastatin Improves Remodeling and Cardiac Function After Myocardial Infarction by an Antiinflammatory Mechanism Rather than by the Induction of Angiogenesis
Ann. Thorac. Surg., June 1, 2006; 81(6): 2217 - 2225.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard
The Role of Statins in Cancer Therapy.
Oncologist, January 1, 2006; 11(3): 306 - 315.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. E. Epstein, E. Stabile, T. Kinnaird, C. W. Lee, L. Clavijo, and M. S. Burnett
Janus Phenomenon: The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis
Circulation, June 15, 2004; 109(23): 2826 - 2831.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, P. Stewen, and F. Fyhrquist
Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells
Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2096 - H2102.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. K. Liao
Statin Therapy: Having the Good Without the Bad
Hypertension, June 1, 2004; 43(6): 1171 - 1172.
[Full Text] [PDF]


Home page
CirculationHome page
U. Schonbeck and P. Libby
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
F. R. DANESH and Y. S. KANWAR
Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy
FASEB J, May 1, 2004; 18(7): 805 - 815.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S Zbinden, N Brunner, K Wustmann, M Billinger, B Meier, and C Seiler
Effect of statin treatment on coronary collateral flow in patients with coronary artery disease
Heart, April 1, 2004; 90(4): 448 - 449.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
C. R. Wolfram Kuhlmann, C. Gast, F. Li, M. Schafer, H. Tillmanns, B. Waldecker, and J. Wiecha
Cerivastatin Activates Endothelial Calcium-Activated Potassium Channels and Thereby Modulates Endothelial Nitric Oxide Production and Cell Proliferation
J. Am. Soc. Nephrol., April 1, 2004; 15(4): 868 - 875.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Wang, M. G. Hasham, I. Isordia-Salas, A. Y. Tsygankov, R. W. Colman, and Y.-L. Guo
Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen
Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1917 - H1923.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Wolfrum, K. S. Jensen, and J. K. Liao
Endothelium-Dependent Effects of Statins
Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 729 - 736.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. P. van Nieuw Amerongen, P. Koolwijk, A. Versteilen, and V. W.M. van Hinsbergh
Involvement of RhoA/Rho Kinase Signaling in VEGF-Induced Endothelial Cell Migration and Angiogenesis In Vitro
Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 211 - 217.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. Shiojima and K. Walsh
Role of Akt Signaling in Vascular Homeostasis and Angiogenesis
Circ. Res., June 28, 2002; 90(12): 1243 - 1250.
[Abstract] [Full Text] [PDF]